Imipramine induced elevation of prolactin levels in patients with HIV/AIDS improved their immune status

West Indian Medical Journal

Volumn 58, Issue 3, 2009, Pages 207-213

  Orlander, H ^a   Peter, S ^a   Jarvis, M ^a   Ricketts Hall, L ^b  

^a Princess Margaret Hospital   (United States)

^b Public Hospitals Authority   (Bahamas)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPRAMINE; PROLACTIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; MALE; PRESCRIPTION; VIRUS LOAD;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ANTI-HIV AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HEALTH STATUS; HIV INFECTIONS; HUMANS; IMIPRAMINE; IMMUNE SYSTEM; MALE; MIDDLE AGED; PROLACTIN; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 71949120773     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: Structure, function, and regulation of secretion. Physiol Rev 2000; 80: 1523-1531 (Pubitemid 30764163)
2. Goffin V, Binart N, Touraine P, Kelly PA. Prolactin: The new biology of an old hormone. Annu Rev Physiol 2002; 64: 47-67. (Pubitemid 34259225)
3. Nagy E, Berczi I. Immunodeficiency in hypophysectomized rats. Acta Endocrinologica 1978; 89: 530-537
4. Yu-Lee LY. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 2002; 57: 435-455
5. Walker SE. Bromocriptine treatment of systemic lupus erythematousos. Lupus 2001; 10: 762-768 (Pubitemid 33048800)
6. Ben-Johnathan N, Mershon J, Allen D, Steinmetz R. Extra pituitary prolactin: Distribution, regulation, functions and clinical aspects. Endocr Rev 1996; 17: 639-1459
7. Dogusan Z, Hooghe R, Verdood P, Hooghe-Peters E. Cytokine-like Effects of prolactin in human mononuclear and polymorphonuclear leukocytes. J Neuroimmunol 2001; 120: 58-66. (Pubitemid 33016725)
8. Bouchard B, Ormandy CJ, D Santo JP, Kelly PA. Immune system development and function in prilactin receptor-deficient mice. J Immunol 1999; 163: 576-582 (Pubitemid 29328058)
9. Berczi, I. Foreword: The neuroimmune Biology of Growth and Lactogenic Hormones in Matera L, Rapaport R, Editors. Growth and Lactogenic Hormones; Neuroimmune biology series, vol.2 Amsterdam: Elsevier, 2002; 5-14.
10. Ivashkiv LB. Jak-STAT Signaling pathways in cells of the immune system Rev immunogenet 2000; 2: 220-230
11. Malone JL, Simms TE, Gray GC, Wagner KF, Burge JR, Burke DS. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr 1990; 3: 144-151
12. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954
13. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-129 (Pubitemid 34786200)
14. Panel on Clinical Practices for Treatment of HIV Infection, DHHS: Guidelines for Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, November 10, 2003; 12.
15. Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E et al. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load. J Infect Dis 1999; 180: 530-533 (Pubitemid 30256342)
16. Panel on Clinical Practices For Treatment of HIV Infection, DHHS: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, November 10, 2003; 12.
17. Scaling Up ARV therapy in Resource-Limited Settings: Guidelines For a Public Health approach, WHO publication June 2002.
18. Panel on Clinical Practices For Treatment of HlV Infection, DHHS: Guidelines for the use of Antiretroviral Agents in Adults and Adolescents, 2006.
19. th International AIDS Conference Durban, South Africa. 2000; Abstract TuOrB417.
20. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157: 1271-1278 (Pubitemid 126449644)
21. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13: 1873-1880 (Pubitemid 29509546)
22. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
23. th Interscience Conference of Antimicrobial Agents and Chemotherapy. Toronto, Canada. 2000; Abstract 699.
24. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116 (Pubitemid 27450659)
25. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat Med 1998; 4: 208-214
26. Angel TA, Stalkup JR, Hsu S. Photodistributed blue gray pigmentation of the skin associated with long term Imipramine use. Int J Dermatolo 2002; 41: 327-329 (Pubitemid 34863299)